Forbes January 20, 2025
Dileep Rao

Venture capital (VC) thrives on risk. Corporations prioritize stable growth. Top-tier VC firm Andreessen Horowitz (AH) often pushes the boundaries of traditional VC and continuously experiments with new strategies, and pivots quickly when strategies fall short.

New Collaboration

Now, AH and Eli Lilly are rewriting the playbook with a pioneering Biotech Ecosystem Fund. This collaboration has the potential to redefine how Corporate VC (CVC) fuels innovation – not just in biotech, but across emerging industries. Here are three key lessons from this partnership that VCs, CVCs and entrepreneurs can use to build the next wave of unicorns.

#1. Top Unicorn Developers Master Early-Stage Venture Risk

Corporations prioritize consistent and growing cash flow and avoid high risk ventures. In contrast, VCs...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Investments, Trends
Related Articles:
Red Rover Health Raises $4 Million in Funding to Grow Healthcare App Store Platform
Medical Device IPOs Could Revive Health Tech Listings
$10.1 Billion Pours Into Digital Health, but Late-Stage Ventures Feel the Pinch
In Competitive Funding Landscape, Behavioral Health Upstarts Must Outlast the ‘Walking Dead’
Life Sciences Investors: Developments to Watch, With Kevin Madagan

Share This Article